Price$43.88+0.72 (+1.67%)
12:00 PM07:45 PM
News · 26 weeks56-58%
2025-11-092026-05-03
Mix4490d
- SEC Filings30(68%)
- Analyst10(23%)
- Other3(7%)
- Earnings1(2%)
Latest news
25 items- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- PRThe Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialIssued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- ANALYSTWolfe Research initiated coverage on Novo Nordisk A/SWolfe Research initiated coverage of Novo Nordisk A/S with a rating of Peer Perform
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- PRFDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profileAverage weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy® HD (~19% regardless of whether patients stayed on treatment**) in the STEP UP trial1In the STEP UP trial, about one in three trial participants taking Wegovy® HD achieved 25% weight loss or higher1This approval for Wegovy® further expands its already robust label inclusive of multiple formulations, including Wegovy® pill, and indications not available with other GLP-1 weight loss medicinesPLAINSBORO, N.J., March 19, 2026 /PRNewswire/ -- Novo Nordisk today announced US Food and Drug Administration (FDA) approval of a new higher dose of Wegovy®, Wegovy® HD (semaglutide) injection 7.
- ANALYSTBernstein initiated coverage on Novo Nordisk A/SBernstein initiated coverage of Novo Nordisk A/S with a rating of Underperform
- ANALYSTBernstein initiated coverage on Novo Nordisk A/S with a new price targetBernstein initiated coverage of Novo Nordisk A/S with a rating of Outperform and set a new price target of $175.00
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- ANALYSTNovo Nordisk A/S downgraded by TD Cowen with a new price targetTD Cowen downgraded Novo Nordisk A/S from Buy to Hold and set a new price target of $42.00
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- ANALYSTNovo Nordisk A/S upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Novo Nordisk A/S from Underweight to Equal-Weight and set a new price target of $40.00
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- ANALYSTNovo Nordisk A/S downgraded by Goldman with a new price targetGoldman downgraded Novo Nordisk A/S from Buy to Neutral and set a new price target of $41.00
- SECSEC Form 6-K filed by Novo Nordisk A/S6-K - NOVO NORDISK A S (0000353278) (Filer)
- ANALYSTNovo Nordisk A/S downgraded by AnalystAnalyst downgraded Novo Nordisk A/S from Overweight to Neutral
- ANALYSTNovo Nordisk A/S downgraded by KeplerKepler downgraded Novo Nordisk A/S from Buy to Hold
NVO FAQ
7 questionsWhat does Novo Nordisk A/S do?
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop...Where does NVO stock trade?
Novo Nordisk A/S (NVO) is listed on NYSE.What sector and industry is NVO in?
Novo Nordisk A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does NVO pay a dividend?
NVO's most recent ex-dividend date was 2026-03-30 with a cash dividend of $0.87 per share. No future ex-date is on file yet.What are analysts saying about NVO?
Novo Nordisk A/S has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-03-26. Recent price targets range from $4000.00 to $4200.00.What companies are similar to NVO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare NVO side-by-side with any of them on Quantisnow.How can I track NVO on Quantisnow?
Quantisnow aggregates Novo Nordisk A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVO to receive live email and push alerts on every new disclosure.